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For over 40 years, S-fluorouracil, frequently combined with folinic acid, has been the
main cytotoxic drug for the treatment of colorectal cancer. In the last decade,
however, new cytotoxic agents have been introduced: raltitrexed, irinotecan ,
oxaliplatin, and oral analogues of S-fluorouracil, i.e. tegafur in combination with uracil
(UFT) and capecitabine. Inaddition, novel biologically targeted therapeutics, i.e.
angiogenesis nhibitors (e.9., bevacizumab), epidermal growth factor receptor
(EGRF)-inhibitors (e.9., cetuximab), farnesyltransferase inhibitors, cell-cycle-
interacting agents, nonsteroidal ntiinflammatory drugs, immunotherapy, and gene
therapy are clinically evaluated, for both single-agent and combination strategies.[1]
At present, mainly S-fluorouracil ombined with folinic acid, or capecitabine, with or
without irinotecan and/or oxaliolatin are chosen for treatment of colorectal cancer in
clinical practice. The use of these agents is increasing due to the addition of second-
and even third-line chemotherapy for metastatic olorectal cancer in case of disease
progression under first-line and second-line treatment, respectively. Also, adjuvant
chemotherapy may be applied for treatment of Dukes' B or stage ll colon cancer as
well, next to Dukes' C or stage lll colon cancer.[2,3] Finally, elderly patients with
colorectal cancer are not to be excluded any longer from chemotherapy, since elderly
patients benefit o the same extent as younger patients from treatment with cytotoxic
agents.[4]
Better systemic hemotherapy has considerably improved prognosis. The median
duration of survival among patients with metastatic olorectal cancer increased from
8 months without chemotherapy to 12 months with S-fluorouracil. The availability of
irinotecan and oxaliplatin, ext to 5-fluorouracil, further extended the median survival
to 21 months.[5] However, treatment with different combinations of these agents is
stil l associated with substantial toxicity.
Currently, the dosage of cytotoxic agents for an individual patient is calculated from
the estimated body surface area of the patient, in contrast to the novel biologicals that
are applied in fixed doses. Toxicity, however, frequently necessitates decreasing the
dosage, extending the dose interval or even discontinuing treatment. Therefore,
along with the increasing concern for quality of life, prevention and management of
chemotherapy induced toxicity is of major clinical importance.
Risk factors with predictive value for toxicity have been found in several studies.
These risk factors are often determined by the pharmacokinetic and pharmacody-
namic properties of the drug. In chapter 1, the risk Íactors for toxicity of the cytotoxic
agents 5-fluorouracil, raltitrexed, irinotecan and oxaliplatin in the treatment of
advanced colorectal cancer are considered. An analysis of toxicity data of different
dose regimens of these agents is also included, since the toxicity profile of cytotoxic
agents is known to be dependent on the drug administration schedule used.
For S-fluorouracil, age, gender, performance status, genetic polymorphism of
dihydropyridine d hydrogenase (DPD), drug administrat ion schedule, c ircadian rythm
of plasmaconcentrations, history of previous chemotherapy-related diarrhea,
xerostomia, low neutrophil levels, and drug-drug interactions have been identified as
affecting chemotherapeutic oxicity. For raltitrexed, gender and renal and hepatic
impairment,  and for oxal iplat in,  renal impairment and circadian rythm of plasma
concentrations, respectively, can be considered as risk factors for toxicity. In addition,
age, performance status, bilirubinaemia, genetic polymorphism of uridine 5'-
diphosphate-glucuronyltransferase-1A1 (UDPGT-1A1), and drug administrat ion
schedule have been shown to be related to irinotecan toxicity. The literature suggests
that dose adjustment based on these risk factors can be used to individualise the
dose in order to decrease toxicity and to improve the therapeutic index. This also
applies to therapeutic drug monitoring, that has been shown to be effective in
controlling the toxicity of 5-fluorouracil in some studies.
Future research is warranted to assess the potential advantage of dose
individualisation f chemotherapy founded on risk factors, next to or over direct dose
calculation from the estimated body surface area, with regard to toxicity, therapeutic
index, and quality of life, in patients with advanced colorectal cancer. When this
concept appears to be sui table for implementat ion in cl in ical  pract ise, the cl in ical
pharmacist may play a vital role in dose individualisation based on risk factors.
In order to reduce toxicity, identifrcation a d management of toxicity signs at their first
appearance are needed, especially with the introduction ofseveral combinations of 5-
FU, ral t i t rexed, i r inotecan and oxal iplat in,  in numerous dosing schedules, leading to
different toxicity profiles. Therefore, toxicity management should be individualized to
anti-cancer agent(s), dosage schedule and patient. Therapeutic drug monitoring of 5-
fluorouracil and chronomodulation f 5-fluorouracil and oxaliolatin have been shown
to limit toxicity in clinical trials. However, these concepts are not implemented in
clinical practice yet.
To date, dose adjustment and intensive supportive measures are the main tools for
toxicity control in the treatment oÍ colorectal cancer. Therefore, in chapter 2,
supportive measures to prevent or alleviate toxicity symptoms of S-fluorouracil,
raltitrexed, irinotecan and oxaliplatin in the treatment of colorectal cancer, are
considered, based on study results. The main toxicity effects of these agents are
myelosuppression, oral mucositis, diarrhoea, acute cholinergic syndrome, nausea
and emesis, neurotoxicity, hand-foot syndrome and other cutaneous adverse eÍfects,
ocular toxicity, cardiotoxicity, small bowel toxicity, asthenia, elevated liver
transaminase l vels, and alopecia. The incidence and gravity of these adverse
effects are more or less related to the agent and administration schedule involved.
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The supportive measures and recommendations include the use of specific drugs,
alterations of administration schedule, and several non-pharmacological methods. ln
addition, guidelines for dosage adjustments when toxicity occurs are presented.
These recommendations and guidelines are based on data from clinical trials,
manufacturer's guidelines for dosage adjustment, and guidelines from expert panels
and associations of oncologists.
For optimal toxicity management, patients hould be considered individually, while
patients, nurses and physicians hould co-operate to identify and treat toxicity
symptoms in an early stage of their development.
Dose adaptation based on pharmacokinetic parameters has been shown to decrease
the toxicity of some S-fluorouracil-based continuous infusion regimens. However, 5-
FU is frequently administered by bolus injection or short infusion. One of the most
common treatment regimens currently in use is the Northern Central Cancer
Treatment Group (NCCTG)-Mayo Clinic regimen:20 mglm2 folinic acid + 425 mglm2
5-FU bolus or short infusion for 5 consecutive days, every 4 to 5 weeks. In a
prospective study, the relationship between 5-fluorouracil pharmacokinetics in plasma
and in saliva, and toxicity was investigated in40 patients receiving the combination of
5-fluorouracil and Íolinic acid according to the Mayo-regimen.(chapter 3)
The overall non-hematological and hematological toxicity, appeared not to be
statistically significant related to the area-under-the-curve in plasma (AUCp) or in
salica (AUCs), nor to the maximum concentration measured in plasma (Cmaxp) or in
sal iva (Cmaxs).  This also appl ies to the maximum mucosit is grade only.  Al though
statistically significant, the correlation between the AUCp and AUCs was relatively
low, implying that salivary pharmacokinetics are not accurately predictive of plasma
pharmacokinetics. Based on this results, pharmacokinetic parameters do not seem to
be adequately predictive for overall toxicity nor for oral mucositis only. Therefore, the
application of pharmacokinetic parameters i  not appropriate for identification of
patients at risk for developing toxicity from treatment with S-fluorouracil according to
the Mayo-regimen. At the present time, toxicity of 5-fluorouracil should be controlled
by dose adjustments and supportive measures. These supportive measures include
haematopoietic Colony Stimulation Factors (CSF) for prevention of myelosuppression
and antibacterials for febrile neutropenia, oral cooling with ice-chips for alleviation of
oral mucositis, loperamide and rehydration for treatment of diarrhea, and
metoclopramide for nausea or emesis.(chapter 2) Atternatively, in several studies risk
factors with predictive value for S-fluorouracil toxicity have been identified, e.g. age,
gender, performance status, genetic polymorphism regarding thymidylate synthetase
and dihydropyrimidine d hydrogenase (DPD), chronopharmacology, that warrant
future research in order to control toxicity.(chapter 1)
In chapter 4, plasma and urinary pharmacokinetics of oxaliplatin i  33 colorectal
cancer patients are described. Pharmacokinetics of oxaliolatin were determined on
the basis of platinum (Pt)-levels in plasma-ultrafiltrate. A population pharmacokinetic
model for platinum, as a reflection of oxaliplatin pharmacokinetics, was developed.
This model may be used to investigate the predictive value of pharmacokinetics for
the toxicity of oxaliplatin. The dose-limiting toxicity of oxaliplatin is a cumulative
neuropathy, that usually develops after several treatments courses. When a
relationship between pharmacokinetics and toxicity of oxaliplatin is assessed, the
model can be used for prediction and, subsequently, prevention of neuropathy in
individual oatients.
Moreover, the relationship between the amount of Pt in 24h urine and in fractionated
urine collection periods was established. The high correlation coefficients found
indicate that fractionated urine samples in the first 8 hours and the first 10 hours may
replace more time consuming 24h urine collection in order to determine individual
urinary pharmacokinetics.
As described in chapter 2, drug interactions may influence fficacy and toxicity of
cytotoxic treatment significantly, that is caused in part by the low therapeutic index,
i.e. ratio of efficacy profits and toxicity detriment, of cytotoxic drugs. The number of
possible drug-interactions with cytotoxic drugs has been growing over the years,
along with an increase of polypharmacy, especially in the elderly population. In
general, cytotoxic drug are administered inan outpatient setting, after preparation
and delivery by the hospital pharmacy department, while co-medication of non-
cytotoxic agents are usually received from the community pharmacy. This may lead
to incomplete medication surveillance. Therefore, a study was conducted to potential
drug interactions with 5- fluorouracil (chapter 5), and with irinotecan and oxaliplatin
(chapter 6), respectively. Literature was examined for interactions with S-fluorouracil,
and with irinotecan and oxaliplatin. These interactions were classified for
documentation evidence and severity level by a panel of medical oncologists and
pharmacists. In addition, the clinical significance was determined on a 5 level-scale.
In l i terature, 17 interact ions with 5-f luorouraci l  were found, of which 11 were cl in ical ly
significant.(chapter 5) Subsequently, all co-medication of 122 colorectal cancer
oatients that were treated with 5-fluorouracilifolinic acid was examined for interactions
with 5-fluorouracil. Inaddition, toxicity of 5-fluorouracil/folinic acid in these patients
was determined according to the NCI-CTCriteria.
Analysis of the co-medication revealed possible clinically significant interactions in4
patients, that used hydrochlorothiazide (2 patients) or folic acid (2 patients). The
occurence of the interaction between S-fluorouracil and folrc acid may increase in
future years, because of the foreseen growing use of folic acid for treatment of
hyperhomocysteine
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hyperhomocysteinemiae for prevention of cardiovascular events. However, since the
dosage of folinic acid that is used for this indication is relatively low, the clinical
significance of this interaction is l imited.
Toxicity percentages of S-fluorouracil/folinic a id in this patient group matched with
percentages from clinical trials found in l iterature. Consequently, these results
confirm that treatment of colorectal cancer with the combination of 5-fluorouracil/-
folinic acid is associated with substantial toxicity.
Analogously to the former study, co-medication of 98 patients, that were treated with
irinotecan (75 patients) and/or oxaliplatin (52 patients), was evaluated for the
occurrence of clinically significant interactions.(chapter 6) Among the interactions,
selected from literature, the expert panel identif ied ' l  1 clinically significant interactions
with irinotecan and 1 with oxaliplatin. Of these, dexamethasone (45 patients),
loperamide (64 patients), and phenytoin (1 patient) were found as co-medication in
irinotecan{reated patients. Assuming dexamethasone and loperamide being applied
deliberately for treatment of nausea and vomiting, and diarrhea, respectively, only
one patient had been exposed to a significant interaction, i.e. with phenytoin.
Although the occurence of clinically significant interactions in both studies, regarding
S-fluorouracil, and irinotecan and oxaliplatin, was low, the agents with significant
interacting potential, as indicated by the expert panels, should be added to
i nteractions-databases for medication-su rveil ance.
In two phase ll l  tr ials, capecitabine, a new oral prodrug of 5-fluorouracil, was at least
as effective as 5-fluorouracil plus folinic acid in the treatment of metastatic colorectal
cancer. In addition, capecitabine showed a more favourable toxicity profi le, as well as
the convenience of oral administration at home. In chapter 7. the results are
presented of a cost-benefit analysis to assess the pharmacoeconomic profi le of
capecitabine compared with S-fluorouracil/folinic a id, given according to the Mayo
regimen, for colorectal cancer patients treated in the Netherlands. Based on data
from 65 patients, this cost-benefit analysis revealed that the higher acquisit ion costs
of capecitabine were more than compensated for by the reduced costs for travel
expenses, hospital care (l imited number of outpatient visits vs inpatient treatment for
S-fluorouracil/folinic a id), and toxicity management. Baseline savings were estimated
at € 1610 for pall iative treatment and € 934 for adjuvant treatment, suggesting that
treatment of colorectal cancer with oral capecitabine is cost-saving in the Netherlands
compared with S-fluorouracil plus folinic acid administered according to the Mayo
regimen.
Recommendations
In the present hesis, various aspects of chemotherapy in the treatment of colorectal
cancer are considered that are more or less appropriate for interventions by clinical
pharmacists. For instance, risk factors for toxicity, that are dependent of the cytotoxic
agent used, are potential starting-points for toxicity control. Currently, the clinical
pharmacist may be involved in guideline discussions to choose the dose-regimen of
S-fluorouracil or irinotecan with the most suitable toxicity profile for individual patients,
next to calculating the dose from the estimated body surface area. In addition, dose
adaptation based on performance status and age is a target for toxicity control of
these two agents. In future, along with the increasing interest in pharmacogenetics,
genetic polymorphism of the enzymes dihydropyridine d hydrogenase (DPD) and
uridine 5'-diphosphate-glucuronyltransferase-1A1 (UDPGT-1A1 ) may lead to
screening of patients for altered pharmacokinetics of S-fluorouracil and irinotecan,
respectively, inorder to prevent significant toxicity in patients with enzyme-
polymorphism.[6,7]
The supportive measures for prevention or alleviation of toxicity symptoms that are
presented can be used for development of treatment protocols as well as individual
control of treatment-related toxicity by the clinical pharmacist.
Nowadays, therapeutic drug monitoring oí cytotoxic agents is mainly applied in
investigational settings. In clinical practice, no cytotoxic agent used in the treatment
of colorectal cancer is routinely monitored based on plasma-concentrations. Our
results regarding 5-fluorouracil do not oppose this practice, whereas the
pharmacokinetic model that has been established for oxaliplatin eeds further
investigation with regard to toxicity control. However, since therapeutic drug
monitoring has been shown to be effective in controlling the toxicity of S-fluorouracil in
some studies, this concept stil l offers potential benefits that have to be elucidated.
Several drug-interactions with S-fluorouracil and irinotecan have been shown to be
clinically significant, and are therefore rroneously disregarded in medication-
surveillance in (Dutch) clinical practice. The clinical pharmacist should be on the alert
for these interacting agents, as well as yet non-identified agents that may interact
significantly with other cytotoxic drugs, and intervene if necessary.
Pharmaco-economics s becoming increasingly important in assessing the benefits of
new (cytotoxic) drugs. In fact, as from 2005, manufacturers are required to deliver a
pharmaco-economic evaluation in order to obtain a registration licence in the
Netherlands.[8] In this thesis, capecitabine has been proven to be cost-saving in
comparison with 5-fluorouracil/folinic acid in the treatment of Dutch colorectal cancer
patients. As for other new agents, the clinical pharmacist can make an essential
contribution to the performance and the interpretation f this type of investigation,
both on a national scale and in a local setting. Accordingly, the Netherlands
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Association of Hospital Pharmacists should anticipate to this development by offering
education and by supporting and coordinating studies in this area.
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